Frederick Rothberg, DPM
Foot & Ankle Surgery · Toms River, NJNPI 1033115738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,393 of the $61,323 with a category attached, or 65.9%. Smith+Nephew accounts for 95.3% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $16,361 and has fallen 56.1% since, to $7,187 in 2025. Among foot & ankle surgery clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $215.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$58K
- Organogenesis Inc.$1K
- Musculoskeletal Transplant Foundation Inc.$616
- Kerecis Limited$117
- Paratek Pharmaceuticals, Inc.$100
- Novo Nordisk$65
- plus $586 from 24 others
What the payments were for
- Consulting fees$10,49117%
- Speaking & faculty fees$40,39366%
- Travel & lodging$4,4867%
- Food & beverage$5,95210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 171 | $58,443 |
| Organogenesis Inc. | 48 | $1,395 |
| Musculoskeletal Transplant Foundation Inc. | 21 | $616 |
| Kerecis Limited | 2 | $117 |
| Paratek Pharmaceuticals, Inc. | 6 | $100 |
| Novo Nordisk | 4 | $65 |
| Pfizer | 4 | $57 |
| Convatec Inc. | 2 | $49 |
| Urgo Medical North America, LLC | 2 | $43 |
| Abbott | 2 | $41 |
| Integra Lifesciences Corporation | 2 | $40 |
| Next Science LLC | 1 | $36 |
| Lilly USA, LLC | 2 | $31 |
| GSK | 2 | $29 |
| Reapplix Inc. | 1 | $25 |
| Stryker | 1 | $21 |
| Biogen | 1 | $19 |
| Valeritas, Inc. | 1 | $18 |
| Advanced Oxygen Therapy Inc. | 1 | $17 |
| Reprise Biomedical, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Merck | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COLLAGENASE SANTYL$23,005
- Santyl$14,869
- NA$12,738
- REGRANEX$12,167
- Grafix$11,425
- Oasis$10,091
- GRAFIX PL$9,819
- Grafix XC$9,819
- Kerecis Omega3 Marigen$336
- Iodosorb Ointment 40g USA$334
- PuraPly$128
- Apligraf$124
- Dermagraft$124
- Puraply/Affinity/NuTech$124
- Kerecis Omega3 SurgiClose$112
- Kerecis Omega3 GraftGuide$112
How this compares
$61,323 in reported general payments places this provider in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 58 | $31,616 |
| Doxycycline Hyclate | 134 | $1,414 |
| Mupirocin | 145 | $1,026 |
| CiclopiroxCiclopirox Olamine | 37 | $734 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 36 | $644 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $330 |
| Cephalexin | 29 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $58,443 | $31,61658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.
Other foot & ankle surgery in Toms River
- Matthew RegulskiToms River$843K
- Girish NairToms River$60K
- Avik MukherjeeToms River$13K
- John CozzarelliBelleville$932K
- Michael SubikLyndhurst$529K
- Krupa PatelMorris Plains$281K
- Johanna GodoyWayne$254K
- Andrew BriefRidgewood$253K
- Mark SolomonCedar Knolls$232K
- Evan AdlerOld Bridge$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.